Dublin, May 20, 2025 (GLOBE NEWSWIRE) -- The "Global Antibody Drug Conjugates Market - 2025-2035: Focus on Product, Application, Target, Payload Type, Linker Type, Linker Technology, and Geography" has been added to ResearchAndMarkets.com's offering.
The global antibody drug conjugate (ADC) market is undergoing significant growth, spurred by the rising prevalence of cancer, innovations in targeted therapies, and a growing demand for treatments that are more effective and less toxic than traditional options. ADCs, which combine the specificity of monoclonal antibodies with the potency of cytotoxic drugs, offer targeted delivery of chemotherapy to cancer cells, reducing harm to healthy tissues. As the landscape of cancer treatment evolves, ADCs are receiving considerable attention for their ability to provide precise therapies with better therapeutic outcomes.
The increasing global burden of cancer, driven by an aging population and lifestyle changes, stands as a principal factor in market expansion. With many cancers still lacking effective treatments, ADCs are becoming increasingly desirable due to their potential to offer successful treatment avenues with reduced side effects compared to conventional chemotherapy.
Technological advancements in ADCs, particularly in linker chemistry, cytotoxic drugs, and monoclonal antibodies, have greatly improved their efficacy and safety. These improvements enable precise cancer cell targeting while minimizing damage to healthy cells, enhancing their attractiveness as an alternative to traditional treatments and fueling market growth.
Oncology research investments and the development of novel therapeutics have further propelled the ADC market. Many pharmaceutical companies are now focusing on ADCs as promising cancer treatment strategies, leading to more partnerships and collaborations to accelerate their development and commercialization. Regulatory approvals, such as those by the U.S. FDA for Kadcyla and Adcetris, have bolstered market confidence and adoption, paving the way for more widespread use in clinical practices.
Targeted therapies like ADCs have become essential in cancer treatment, providing precision in targeting cancer cells while minimizing the side effects associated with conventional chemotherapy. This shift towards personalized and effective therapies is driving ADC demand, as they combine the benefits of immunotherapy and chemotherapy to deliver improved patient outcomes.
Key market players include F. Hoffmann La Roche Ltd, Daiichi Sankyo Company, Limited Seagen Inc., Gilead Sciences, Inc., Takeda Pharmaceutical Company Limited, Pfizer Inc., Astellas Pharma Inc., AstraZeneca, ADC Therapeutics SA, and Immunogen, Inc.
North America leads the global ADC market due to its advanced healthcare infrastructure, robust research capabilities, and significant oncology drug development investments. The United States is particularly critical, driven by multiple FDA ADC approvals and its extensive pharmaceutical sector. Europe also presents a significant market, with Germany, the UK, and France leading in market adoption, supported by European Medicines Agency approvals. The Asia-Pacific region is set for the highest growth, underpinned by rising cancer rates and improving healthcare infrastructure, particularly in China, Japan, and India.
Key Topics Covered:
Executive Summary
Scope of the Study
Research Methodology
1. Global Antibody Drug Conjugates Market Overview
1.1 Market Outlook
1.2 Industry Outlook
1.3 Business Dynamics
2. Global Antibody Drug Conjugates Market by Product, in US$
2.1 Overview
2.2 Growth Share Matrix
3. Global Antibody Drug Conjugates Market by Application, in US$
3.1 Overview
3.2 Growth Share Matrix
4. Global Antibody Drug Conjugates Market by Target, in US$
4.1 Overview
4.2 Growth Share Matrix
5. Global Antibody Drug Conjugates Market by Payload Type, in US$
5.1 Overview
5.2 Growth Share Matrix
6. Global Antibody Drug Conjugates Market by Linker Type, in US$
6.1 Overview
6.2 Growth Share Matrix
7. Global Antibody Drug Conjugates Market by Linker Technology, in US$
7.1 Overview
7.2 Growth Share Matrix
8. Global Antibody Drug Conjugates Market by Geography, in US$
8.1 Overview
8.2 Growth Share Matrix
8.3 North America Antibody Drug Conjugates Market
8.4 Europe Antibody Drug Conjugates Market
8.5 Asia Pacific Antibody Drug Conjugates Market
8.6 Latin America Antibody Drug Conjugates Market
8.7 MEA Antibody Drug Conjugates Market
9. Global Antibody Drug Conjugates Market - Competitive Benchmarking and Company Profiles
9.1 Competitive Benchmarking
9.2 Competitive Landscape
9.3 Company Profiles
- F. Hoffmann-La Roche Ltd.
- Daiichi Sankyo Company, Limited
- Seagen Inc.
- Gilead Sciences, Inc.
- Takeda Pharmaceutical Company Limited
- Pfizer Inc.
- Astellas Pharma Inc.
- AstraZeneca
- ADC Therapeutics SA
- Immunogen, Inc.
- Zydus Group
- GSK plc.
- Synaffix BV
For more information about this report visit https://www.researchandmarkets.com/r/mfkx59
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
